On Oct. 26, 2020, PerkinElmer announced that its PKampﾙ Respiratory SARS-CoV-2 RT-PCR Panel had received clearance to be marketed as an in vitro diagnostic device in more than 30 countries by meeting the requirements of the European In Vitro Diagnostic Directive This test was under review by the FDA for Emergency Use Authorization.

The multi-analyte panel enables labs to detect and differentiate between SARS-CoV-2, influenza A viruses, influenza B viruses and respiratory syncytial virus in a single test.